GlassScriptPhysician profile
Allison Lee Wallick
NPI 1821592312
$928.66
in general payments reported to CMS, 2019-2025
21 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.08 · 2022: $170 · 2023: $102 · 2024: $436 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $720.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $189.85 | 2021-2025 | Epclusa |
| Abbvie INC. | $131.72 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.93 | 2023-2025 | |
| Abbott Laboratories | $77.26 | 2022-2024 | Freestyle Libre 3 |
| Amgen INC. | $67.41 | 2021-2024 | Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $46.65 | 2023-2025 | Rexulti, Abilify Maintena |
| Novo Nordisk INC | $44.16 | 2024 | Wegovy, Ozempic, Rybelsus |
| Alkermes, INC. | $36.46 | 2022-2024 | Vivitrol |
| Sanofi-Aventis U.S. LLC | $31.56 | 2023-2024 | |
| Vanda Pharmaceuticals INC. | $30.74 | 2024-2025 | Fanapt, Hetlioz |
| Lilly USA, LLC | $27.91 | 2023-2024 | Jardiance, Zepbound, Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.44 | 2025 | Caplyta |
| Pfizer INC. | $19.35 | 2024 | |
| Insulet Corporation | $18.80 | 2024 | Omnipod |
| Teva Pharmaceuticals USA, INC. | $18.72 | 2025 | Austedo Xr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $17.40 | 2025 | Airsupra |
| Sanofi Pasteur INC. | $14.92 | 2025 | |
| Genzyme Corporation | $14.77 | 2025 | |
| Hologic Sales and Service, LLC | $13.82 | 2024 | Thinprep 2000 Processor |
| Ascensia Diabetes Care US INC. | $13.62 | 2023 | |
| Neurocrine Biosciences, INC. | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Wallick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.